GSK Faces Legal and Financial Challenges Amid Major Corporate Shifts
Pharmaceutical giant GSK is experiencing significant developments including its exit from the Biotechnology Innovation Organization and a $2.2 billion settlement over Zantac lawsuits. Despite the tumult, GSK's share value increased by 6% following the settlement, while the company announced a quarterly dividend of 15 pence amidst broader concerns over its financial strategies and the future of dividend payments.